Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509392 | 0.91 | FAAH (0.42) | ALDH1A1FAAHHTR1AF10NAMPT | |
| SCHEMBL2192802 | 0.86 | ALDH1A1 (0.43) | ALDH1A1FAAHHTR1ANAMPTCYP3A4 | |
| SCHEMBL12509175 | 0.86 | ALDH1A1 (0.46) | ALDH1A1FAAHNAMPTCYP3A4CYP2D6 | |
| SCHEMBL2197160 | 0.85 | FAAH (0.44) | ALDH1A1FAAHNAMPTCYP3A4CYP2D6 | |
| SCHEMBL2195603 | 0.84 | FAAH (0.47) | ALDH1A1FAAHF10CYP3A4CYP2D6 | |
| SCHEMBL2196898 | 0.84 | FAAH (0.40) | ALDH1A1FAAHNAMPTCYP3A4CYP2D6 | |
| SCHEMBL12509280 | 0.82 | ALDH1A1 (0.46) | ALDH1A1FAAHNAMPTCYP3A4CYP2D6 | |
| SCHEMBL12509264 | 0.81 | CHRNB2 (0.46) | ALDH1A1FAAHNAMPTCYP2D6 | |
| SCHEMBL12509270 | 0.80 | LMNA (0.46) | ALDH1A1F10 | |
| SCHEMBL12509094 | 0.80 | FAAH (0.42) | ALDH1A1FAAHNAMPTCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | claimed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | claimed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | ALDH1A1 259/4885FAAH 1/4885HTR1A 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.